GSK to establish Asian headquarters in Singapore
UK pharma major GlaxoSmithKline (LSE: GSK) is establishing a new global headquarters for Asia in Singapore.
The company has signed an agreement with Bousted Development Partnership joint venture entity to develop and lease a new building which will make the new global headquarters for Asia. Located in the Rochester Park area of Singapore, GSK will move all employees currently working in the Gateway West site to the new headquarters in the second half of 2017.
The consumer health care, pharma and vaccines markets are forecast to grow significantly faster in countries covered by the Asia global headquarters than in the rest of the world, and the new site will support local GSK businesses across the region. The eight-storey, nearly 15,000 square metres facility will have capacity for up to 1,000 employees across GSK’s pharmaceuticals, vaccines and consumer healthcare businesses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze